Skip to main content
SpringerLink
Log in

Prognostic Factors for Metastatic Kidney Cancer

  • Chapter
Kidney Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 116))

Abstract

Metastatic renal cell carcinoma is associated with a poor prognosis, a result of the lack of effective systemic therapy.’ Conventional cytotoxic chemotherapy and hormone therapy lack significant antitumor effect in the treatment of metastatic RCC. Response rates to standard cytotoxic chemotherapies are less than 10%02and hormonal therapy is inactive (antiandrogens, antiestrogens, androgens, progestins), with response rates of 1-2%.The rare but consistent incidence of spontaneous tumor regression,plus the naturally occurring phenomenon of lymphocytic infiltration in the renal tumors of untreated patients,’ instigated the study of immunotherapy against renal cell cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Motzer RJ, Russo P, Nanus DM, Berg WJ. Renal cell carcinoma. CurrProblCancer. 1997;21(4): 185–232.

    CAS  Google Scholar 

  2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma.N Engl J Med.1996;335(12):865–75.

    Article  PubMed  CAS  Google Scholar 

  3. Fairlamb DJ. Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer. 1981;47(8):2102–6.

    Article  PubMed  CAS  Google Scholar 

  4. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.J Urol.1993;150(2 Pt 1):463–6.

    PubMed  CAS  Google Scholar 

  5. Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.Arch Surg.I990;125(2):200–5.

    Article  PubMed  CAS  Google Scholar 

  6. Holan V, Kolmo K, Minowada J. Natural human interferon-alpha augments interleukin-2 production by a direct action on the activated IL-2-producing T cells.J Interferon Res.1991;11(6): 319–25.

    Article  PubMed  CAS  Google Scholar 

  7. .Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin2. J Exp Med.1984;160(4):1147-69.

    Article  PubMed  CAS  Google Scholar 

  8. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma.J Clin Oncol.2000;18(9)1928–35.

    PubMed  CAS  Google Scholar 

  9. Wirth MP. Immunotherapy for metastatic renal cell carcinoma.Urol Clin North Am. 1993; 20(2):283–95.

    PubMed  CAS  Google Scholar 

  10. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.J Clin Oncol.1993;11(9)1809–16.

    PubMed  CAS  Google Scholar 

  11. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma.J Urol.1986;136(2): 376–9.

    PubMed  CAS  Google Scholar 

  12. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.Cancer Res.1988;48(24 Pt 1):7310–3.

    PubMed  CAS  Google Scholar 

  13. De Forges A, Rey A, Klink M, Ghosn M, Kramar A, Droz J. Prognostic Factors of Adult Metastatic Renral Carcinoma: A Multivariate Analysis.Seminars in Surgical Oncology.1988;4:149–54.

    Article  PubMed  Google Scholar 

  14. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha.Eur J Cancer.1994;9(4)1310–4.

    Article  Google Scholar 

  15. .Palmer PA, Vinke J, Philip T, et al. Prognostic Factors for Survival in Patients with Advanced Renal Ccell Carcinoma Treated with Recombinant Interleukin-2.Annals of Oncology.1992;3:475-80.

    PubMed  CAS  Google Scholar 

  16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma.Journal of Clinical Oncology.1999; 17(8):2530–40.

    PubMed  CAS  Google Scholar 

  17. .Chen C, George S. The Bootstrap and Identification of Prognostic Factors via Cox’s Proportional Hazards Regression Model.Statistical Medicine.1985;11:39-46.

    Article  CAS  Google Scholar 

  18. Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma.Semin Urol Oncol.2001;19(2):98–102.

    PubMed  CAS  Google Scholar 

  19. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.J Clin Oncol.2002;20(1): 289–96.

    Article  PubMed  CAS  Google Scholar 

  20. Tsui KH, Shvarts 0, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma-a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.J Urol.2000;163(4)1090–5; quiz 1295.

    Article  PubMed  CAS  Google Scholar 

  21. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma.J Clin Oncol.2002;20(5)1368–74.

    Article  PubMed  Google Scholar 

  22. Reuter VE, Presti JC, Jr. Contemporary approach to the classification of renal epithelial tumors.Semin Oncol.2000;27(2)124–37.

    PubMed  CAS  Google Scholar 

  23. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.J Clin Oncol.2002;20(9):2376–81.

    Article  PubMed  Google Scholar 

  24. Sato K, Tsuchiya N, Sasaki R, et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.Jpn JCancerRes.1999;90(8):874–9.

    CAS  Google Scholar 

  25. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?Clin Cancer Res.1997;3(12 Pt 1):2451–8.

    PubMed  CAS  Google Scholar 

  26. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.]Urol.2000;163(1):343–7.

    Article  CAS  Google Scholar 

  27. .Fisher RI, Coltman CA, Jr., Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. AnnIntern Med.1988;108(4):518-23.

    PubMed  CAS  Google Scholar 

  28. .Kamel D, Turpeenniemi-Hujanen T, Vahakangas K, Paakko P, Soini Y. Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma.Histopathology.1994;25(4):339-47.

    Article  PubMed  CAS  Google Scholar 

  29. Lauerova L, Dusek L, Spurny V, et al. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.Oncol Rep.2001;8(3):685–92.

    PubMed  CAS  Google Scholar 

  30. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones.]Exp Med.1989;170(6):2081–95.

    Article  CAS  Google Scholar 

  31. Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F.Interleuldn-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor.Eur J Immunol.1997; 27(3):756–62.

    Article  PubMed  CAS  Google Scholar 

  32. Wittke F, Hoffmann R, Buer J, et al. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma.Br J Cancer.1999;79(7–8): 1182–4.

    Article  PubMed  CAS  Google Scholar 

  33. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. AnnOncol.2002 Sep;13(9):1460–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York, Memorial Sloan Kettering Cancer Center, NY, 10021

    Beverly J. Drucker M.D., Ph.D., Madhu Mazumdar Ph.D. & Robert J. Motzer Ph.D.

Authors
  1. Beverly J. Drucker M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madhu Mazumdar Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert J. Motzer Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, Los Angeles, CA, USA

    Robert A. Figlin

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Drucker, B.J., Mazumdar, M., Motzer, R.J. (2003). Prognostic Factors for Metastatic Kidney Cancer. In: Figlin, R.A. (eds) Kidney Cancer. Cancer Treatment and Research, vol 116. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0451-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0451-1_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5083-5

  • Online ISBN: 978-1-4615-0451-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation